Trial · NCT04256421
Adverse events372
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 372
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Placebo + Atezolizumab | 97 | 246 | 127 |
| other | Anaemia | Blood and lymphatic system disorders | Tiragolumab + Atezolizumab | 86 | 239 | 106 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo + Atezolizumab | 13 | 246 | 21 |
| other | Leukopenia | Blood and lymphatic system disorders | Tiragolumab + Atezolizumab | 13 | 239 | 17 |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo + Atezolizumab | 72 | 246 | 136 |
| other | Neutropenia | Blood and lymphatic system disorders | Tiragolumab + Atezolizumab | 63 | 239 | 91 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo + Atezolizumab | 31 | 246 | 53 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Tiragolumab + Atezolizumab | 29 | 239 | 46 |
| other | Hyperthyroidism | Endocrine disorders | Placebo + Atezolizumab | 17 | 246 | 19 |
| other | Hyperthyroidism | Endocrine disorders | Tiragolumab + Atezolizumab | 16 | 239 | 16 |
| other | Hypothyroidism | Endocrine disorders | Placebo + Atezolizumab | 21 | 246 | 27 |
| other | Hypothyroidism | Endocrine disorders | Tiragolumab + Atezolizumab | 26 | 239 | 26 |
| other | Abdominal pain | Gastrointestinal disorders | Placebo + Atezolizumab | 8 | 246 | 8 |
| other | Abdominal pain | Gastrointestinal disorders | Tiragolumab + Atezolizumab | 12 | 239 | 19 |
| other | Constipation | Gastrointestinal disorders | Placebo + Atezolizumab | 61 | 246 | 67 |
| other | Constipation | Gastrointestinal disorders | Tiragolumab + Atezolizumab | 58 | 239 | 67 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo + Atezolizumab | 37 | 246 | 46 |
| other | Diarrhoea | Gastrointestinal disorders | Tiragolumab + Atezolizumab | 20 | 239 | 24 |
| other | Nausea | Gastrointestinal disorders | Placebo + Atezolizumab | 61 | 246 | 73 |
| other | Nausea | Gastrointestinal disorders | Tiragolumab + Atezolizumab | 59 | 239 | 66 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04256421/events